China Health Insurance: As Funding, Expenditure Grow, How Will Pharma Companies Make Out?
This article was originally published in PharmAsia News
The outflow growth rate for China’s national insurance fund has increased faster than inflow since China implemented healthcare reforms, but the government managed to reverse the trend last year through cost-containment measures. PharmAsia News takes a closer look at how those actions might impact pharma companies.
You may also be interested in...
SHANGHAI - China's prescription drugs market has seen a slowdown in growth in large cities due to implementation of government pilot reimbursement projects that could be adopted nationwide, according to a Sept. 27 Citi report
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.